Michel Aubanel | Molecular Mechanisms Signaling | Research Excellence Award

Published on by Cell Biologist

Mr. Michel Aubanel | Molecular Mechanisms Signaling | Research Excellence Award

Kerry | France

Michel Aubanel is a senior R&D and innovation leader with more than three decades of experience in the flavors, ingredients, and aroma chemicals industry. He has held global leadership roles across major multinational organizations, driving process development, natural extract innovation, flavor optimization, and analytical research. His expertise spans natural and nature-identical molecules, botanical extracts, taste technologies, and advanced flavor delivery systems, with strong involvement in intellectual property creation and patent development. He has led multidisciplinary teams across Europe and the United States and supported global technology deployment across Asia, Africa, and emerging markets, particularly for alcoholic beverages. A recognized contributor to the scientific community, he serves on international science and flavor boards and is an active member of multiple professional chemical societies. His work is reflected in peer-reviewed toxicological publications and granted patents, highlighting a strong commitment to safety, innovation, and sustainable flavor solutions.

Citation Metrics (Scopus)

100
75
50
25
10
0

Citations
59

Documents
7

h-index
3

Citations

Documents

h-index

Featured Publication

Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Published on by Cell Biologist

Prof. Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Department of Medicine and Aging Science, University of Chieti-Pescara “G. d’Annunzio”Chieti | Italy

Francesca Santilli, MD, PhD, is a leading physician-scientist whose work has substantially advanced the understanding of platelet biology, thrombo-inflammation, and cardio-metabolic disease. Her research focuses on mechanisms of platelet activation, interindividual variability in response to low-dose aspirin, and the interplay between inflammation, oxidative stress, and metabolic dysfunction. She has led major national and international projects, including studies on oxidative stress regulation in aspirin-treated diabetes, peripheral blood megakaryocyte maturation, and the effects of JAK inhibitors on thrombopoiesis in inflammatory disease. Her work has also contributed key insights into biomarkers—such as proteomic signatures, microRNAs, and extracellular vesicles—for cardiovascular and metabolic risk stratification. Additional research explores megakaryocyte biology, accelerated platelet turnover, and the impact of emerging therapies including GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors. Through extensive collaborations across molecular medicine, proteomics, rheumatology, cardiology, and infectious diseases, she has established interdisciplinary frameworks linking platelet function to diabetes, obesity, MASLD, and vascular disease. With over 160 high-impact publications and leadership roles in several scientific networks, her research continues to inform clinical translation and therapeutic optimization in thrombosis, hemostasis, and metabolic disorders.

Profiles: Google Scholar | Scopus

Featured Publications: 

antilli, F., Vazzana, N., Liani, R., Guagnano, M. T., & Davì, G. (2012). Platelet activation in obesity and metabolic syndrome. Obesity Reviews, 13(1), 27–42.

Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., & Patrono, C. (2009). Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin “resistance.” Journal of the American College of Cardiology, 53(8), 667–677.

Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., … & Patrono, C. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10(7), 1220–1230.

Caricato, A., Conti, G., Della Corte, F., Mancino, A., Santilli, F., Sandroni, C., … & Antonelli, M. (2005). Effects of PEEP on the intracranial system of patients with head injury and subarachnoid hemorrhage: The role of respiratory system compliance. Journal of Trauma and Acute Care Surgery, 58(3), 571–576.

Santilli, F., Vazzana, N., Bucciarelli, L. G., & Davì, G. (2009). Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Current Medicinal Chemistry, 16(8), 940–952.

Di Castelnuovo, A., Bonaccio, M., Costanzo, S., Gialluisi, A., Antinori, A., … Santilli, F., … & Iacoviello, L. (2020). Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: Survival analysis and machine learning-based findings from the multicentre Italian study. Nutrition, Metabolism and Cardiovascular Diseases, 30(11), 1899–1913.

Vazzana, N., Santilli, F., Cuccurullo, C., & Davì, G. (2009). Soluble RAGE in internal medicine. Internal and Emergency Medicine, 4(5), 389–401.

Davì, G., Santilli, F., & Patrono, C. (2010). Nutraceuticals in diabetes and metabolic syndrome. Cardiovascular Therapeutics, 28(4), 216–226.

Chiarelli, F., Santilli, F., & Mohn, A. (2000). Role of growth factors in the development of diabetic complications. Hormone Research in Paediatrics, 53(2), 53–67.

Davì, G., Chiarelli, F., Santilli, F., Pomilio, M., Vigneri, S., Falco, A., … & Basili, S. (2003). Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation, 107(25), 3199–3203.

Manigrasso, M. R., Ferroni, P., Santilli, F., Taraborelli, T., Guagnano, M. T., … & Davì, G. (2005). Association between circulating adiponectin and interleukin-10 levels in android obesity: Effects of weight loss. The Journal of Clinical Endocrinology & Metabolism, 90(10), 5876–5879.

Junning Ma | Cell Surface Receptors | Best Research Article Award

Published on by Cell Biologist

Dr. Junning Ma | Cell Surface Receptors | Best Research Article Award

Zhejiang University | China

Dr. Junning Ma has developed a multidisciplinary portfolio spanning neurosurgery, neural engineering, biomaterials, and nanomedicine. Their work integrates neural stem cell biology, targeted drug delivery, and tumor microenvironment modulation to create innovative therapeutic strategies for brain diseases. They have conducted advanced postdoctoral and doctoral research at major institutions, contributing to National Natural Science Foundation of China (NSFC) Youth Fund projects and multiple US-funded NIH and AHA grants. Their research focuses on biomimetic nanocarriers, including cell membrane-coated nanoparticles, PLGA-based delivery systems, and fusion-membrane technologies designed for precision therapy of glioma, pituitary adenoma, and ischemic stroke.

Key projects include engineered neural stem cell membrane-coated nanoparticles for stroke targeting, biomimetic nanoplatforms for cancer immunotherapy, and tumor microenvironment–responsive delivery systems. They have also contributed to studies on neuromodulation, neurotrophic factor-based therapy, neural stem cell transplantation, and photothrombotic stroke models. Their publication record includes high-impact journals such as Materials Today Bio, Biomaterials, Nano Letters, Small, and Cell Reports Physical Science, covering topics like vascular-targeting nanoclusters, polyphenol nanoparticles, and membrane-engineered carriers.

Overall, their research advances translational nanomedicine and regenerative neuroscience, with an emphasis on targeted therapies capable of overcoming the challenges of brain tumor heterogeneity, the blood–brain barrier, and ischemic neural injury.

Profiles: Scopus | Orcid

Featured Publications: 

Ma, J., Win, Y., Xiaojian, Z., et al. (2023). Enhanced EPR effects by folliculostellate cell membrane–coated nanoparticles on invasive pituitary adenoma. Materials Today Bio.

Ma, J., Dai, L., Jianbo, Y., et al. (2023). Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology. Biomaterials.

Ma, J., Liu, F., Wendy, C., et al. (2020). Co-presentation of tumor antigens with costimulation via biomimetic nanoparticles for effective cancer immunotherapy. Nano Letters.

Ma, J., Zhang, S., Jun, L., et al. (2019). Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membranes of engineered neural stem cells. Small.

Wan Wan Lin | Inflammation | Best Researcher Award

Published on by Cell Biologist

Prof. Wan Wan Lin | Inflammation | Best Researcher Award

Department of Pharmacology, College of Medicine, NTU | Taiwan

Dr. Wan-Wan Lin is a leading researcher in the fields of pharmacology and immunology, with a strong focus on cellular signaling and innate immune mechanisms. Her work has significantly advanced understanding of signal transduction pathways and their regulation of inflammation and cell death. She has made notable contributions to the study of pattern recognition receptors, inflammasomes, and cytokine-mediated immune responses, particularly in the context of oxidative stress and mitochondrial function. Dr. Lin’s research explores how mitochondrial dynamics and redox balance influence inflammatory signaling and programmed cell death, providing key insights into the molecular basis of immune regulation and inflammatory diseases. Her studies have also shed light on the crosstalk between cellular stress responses and immune activation, offering potential therapeutic targets for controlling excessive inflammation and tissue damage. Recognized for her excellence in research, Dr. Lin has received multiple national awards and continues to contribute to the advancement of pharmacological sciences through her editorial and academic roles. Her integrative approach bridges pharmacology, immunology, and cell biology, driving innovations in the understanding of molecular mechanisms underlying inflammation and innate immunity.

Profile: Orcid

Featured Publications:

Lin, W.-W., Lee, C.-Y., Tsai, M.-C., & Tsaur, M.-L. (1985). Pharmacological study on angusticeps-type toxins from mamba snake venoms. Journal of Pharmacology and Experimental Therapeutics, 233, 491–498.

Lin, W.-W., Chang, P.-L., Lee, C.-Y., & Joubert, F. J. (1987). Pharmacological study on phospholipases A₂ isolated from Naja mossambica mossambica venom. Proceedings of the National Science Council, Republic of China B, 11, 155–163.

Lin, W.-W., Lee, C.-Y., & Burnett, J. W. (1988). Effect of sea nettle (Chrysaora quinquecirrha) venom on isolated rat aorta. Toxicon, 26, 1209–1212.

Chiou, S.-H., Lin, W.-W., & Chang, W.-P. (1989). Sequence characterization of venom toxins from Thailand cobra. International Journal of Peptide and Protein Research, 34, 148–152.

Lee, C.-Y., Lin, W.-W., Chen, Y.-M., & Lee, S.-Y. (1989). Is direct cardiotoxicity the primary cause of death following intravenous injection of the basic phospholipase A₂ from Naja nigricollis venom? Acta Physiologica et Pharmacologica Latinoamericana, 39, 383–391.

Lee, C.-Y., & Lin, W.-W. (1989). Two subtypes of acetylcholinesterase isoenzymes distinguishable by Angusticeps-type toxin F7. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology and Toxicology, 92, 279–281.

Lin, W.-W., Lee, C.-Y., & Chuang, D.-M. (1989). Cross-desensitization of endothelin- and sarafotoxin-induced phosphoinositide turnover in neurons. European Journal of Pharmacology, 166, 581–582.

Lin, W.-W., Chen, Y.-M., Lee, S.-Y., Nishio, H., Kimura, T., Sakakibara, S., & Lee, C.-Y. (1990). Cardiovascular effects of two disulfide analogues of sarafotoxin S6b. Toxicon, 28, 911–923.

Lin, W.-W., Lee, C.-Y., Yasumoto, T., & Chuang, D.-M. (1990). Maitotoxin induces phosphoinositide turnover and modulates glutamatergic and muscarinic cholinergic receptor function in cultured cerebellar neurons. Journal of Neurochemistry, 55, 1563–1568.

Lin, W.-W., & Lee, C.-Y. (1990). Biphasic effects of endothelin in the guinea-pig ileum. European Journal of Pharmacology, 176, 57–62.

Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Shuxin Han | Xinjiang University | China

Dr. Shuxin Han is a distinguished molecular biologist and professor at Xinjiang University, widely recognized for his pioneering work in hepatobiliary and metabolic biology. With a research career spanning over two decades, Dr. Han has made major contributions to understanding how Kruppel-like factors, especially KLF15, regulate endobiotic and xenobiotic metabolism, impacting drug detoxification and metabolic disease mechanisms. He earned his Ph.D. from Kent State University and has held prestigious positions at Harvard Medical School and Case Western Reserve University. His groundbreaking studies have been published in high-impact journals like Nature Metabolism and Nature Communications, with several articles naming him as first or corresponding author. In addition to research, Dr. Han serves as a reviewer for top-tier journals in pharmacology, hepatology, and clinical science. He is also an academic leader, currently shaping the next generation of scientific talent and metabolic disease research in China.

Publication Profile: 

Scopus

Education:

Dr. Shuxin Han began his academic journey in Animal Sciences, earning a bachelor’s degree from Anhui Agricultural University (1994–1998). He advanced to a research assistant role at Peking University (1999–2000), where he deepened his scientific foundation. He then moved to the U.S. to pursue a Master’s in Biology at Temple University (2000–2003), followed by a Ph.D. in Molecular Biology from Kent State University (2004–2009), focusing on metabolic biology and gene regulation. This progression from general animal sciences to highly specialized molecular biology reflects a systematic and deep commitment to biomedical research. His strong academic preparation laid the foundation for a research career investigating how transcriptional regulators impact health and disease. Dr. Han’s training spans world-class institutions across both China and the United States, equipping him with diverse scientific perspectives and techniques.

Experience:

Dr. Shuxin Han has accumulated rich research and academic experience over nearly 30 years. His early career included a pivotal research assistant role at Peking University, followed by advanced training in biology and molecular biology at Temple and Kent State Universities. He completed prestigious postdoctoral training at Harvard Medical School (2009–2012) and Case Western Reserve University (2012–2015), where he later became a Senior Research Associate (2015–2019). He returned to China in 2019 as a Researcher at the University of Science and Technology of China First Affiliated Hospital, simultaneously engaging in academic duties at the university until 2023. Currently, he serves as a Professor and Academic Leader at Xinjiang University. Throughout his career, Dr. Han has built strong international collaborations, led research groups, and guided innovative projects in metabolic biology, demonstrating his leadership, research excellence, and academic mentorship capabilities.

Research Focus:

Dr. Shuxin Han’s research centers on the molecular regulation of metabolism, particularly focusing on the hepatobiliary and gastrointestinal systems. His work has elucidated the critical role of the Kruppel-like factor (KLF) family, especially KLF15, in controlling endobiotic and xenobiotic metabolism (EXM). These pathways govern how the body metabolizes both internal compounds and external substances like drugs. Dr. Han’s studies have shown that KLF15 acts as a master regulator, influencing drug resistance, liver injury, and metabolic homeostasis. His discoveries offer new insight into personalized medicine and treatment for metabolic disorders and drug-related toxicities. With numerous first-author and corresponding-author publications in journals such as Nature Metabolism, Nature Communications, and Drug Metabolism and Disposition, his work has significantly impacted both fundamental science and clinical applications. He is also active in peer-reviewing for top-tier journals and is recognized for his leadership in translational research.

Publications Top Notes:

  1. Unveiling KLF15 as the Key Regulator of Cyclosporine A Metabolism and Adverse Effects – Drug Metabolism and Disposition, 2025

  2. Distribution and Functional Significance of KLF15 in Mouse Cerebellum – Molecular Brain, 2025

  3. Personalized Statin Therapy: Targeting Metabolic Processes – Heliyon, 2025

  4. Current Status and New Directions for Hepatocellular Carcinoma Diagnosis – Liver Research, 2024

  5. KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury – Drug Metabolism and Disposition, 2024

  6. Advancing Drug Delivery and Bioengineering in Liver Research – Bioengineering and Translational Medicine, 2024

  7. Advances in IL-7 Research on Tumor Therapy – Pharmaceuticals, 2024 (Co-author)

  8. Pathogenic Mechanisms in Alcoholic Liver Disease – Journal of Translational Medicine, 2023

  9. Beta-Hydroxybutyrate Effects on iPSC-Derived Cardiac Myocytes – Biomolecules, 2022

  10. Interactions Between Intestinal Flora and Bile Acids – International Journal of Molecular Sciences, 2022 (Corresponding author)

Conclusion:

In conclusion, Dr. Shuxin Han is a highly deserving candidate for the Best Researcher Award. His pioneering work on KLF15 and metabolic regulation has reshaped fundamental understanding in the field of hepatobiliary biology and pharmacology. His academic background, research productivity, international experience, and editorial service all reflect a well-rounded and impactful scientist. While there is room to increase clinical translation and international engagement, the depth, originality, and consistency of his research make him a strong contender for this recognition. Honoring Dr. Han with this award would acknowledge a career dedicated to scientific advancement with substantial implications for human health and drug therapy.

Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Published on by Cell Biologist

Dr. Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Dr. Kai Zhao | shandong first medical university | China

Kai Zhao is a dedicated biomedical scientist specializing in cell biology and translational medical research. Affiliated with the Central Hospital and Shandong First Medical University, Kai has focused on molecular mechanisms underlying diseases such as osteosarcoma and neurodegeneration. Their expertise includes mitophagy regulation, exosomal gene biomarkers, and multi-omics analyses, aiming to discover novel therapeutic targets. Kai has contributed significantly to understanding how cellular degradation pathways influence disease progression, with published work in prominent journals. They hold key roles in both clinical and research settings, bridging basic science and patient care. Their collaborative work and innovative approach have garnered attention in the biomedical community, underscoring their role as a rising leader in cell biology research.

Publication Profile: 

Orcid

Education:

Kai Zhao completed their foundational studies in medicine at a prestigious medical university in China, followed by advanced graduate training focusing on cellular and molecular biology. Their education provided a strong grounding in clinical medicine combined with rigorous laboratory research skills. They further specialized through postgraduate work that integrated molecular biology techniques and omics technologies, developing expertise in the mechanisms of disease at a cellular level. This multidisciplinary education enabled Kai to pursue research at the interface of clinical practice and experimental biology. They have also completed specialized training in bone biomechanics and metabolism, as well as spinal surgery, enhancing their ability to conduct translational research. Continuous professional development through workshops, conferences, and collaborative projects complements their formal education, keeping them updated on cutting-edge scientific advances.

Experience:

Kai Zhao has extensive experience working at the Central Hospital Affiliated with Shandong First Medical University, where they contribute both clinically and in research. Their experience includes investigating molecular pathways in osteosarcoma and neurodegenerative models using cell lines such as SH-SY5Y. Kai has led projects applying multi-omics data to identify exosomal gene biomarkers and therapeutic targets like mifepristone. Their role in the Spinal Surgery Department and Bone Biomechanics Laboratory has provided hands-on clinical insight, informing their research on bone and spinal disorders. Kai collaborates with multidisciplinary teams, combining clinical knowledge with molecular techniques. Their publication record reflects proficiency in advanced methodologies such as mitophagy analysis, molecular degradation pathways, and biomarker discovery. Kai also mentors junior researchers and participates in academic dissemination through publications and conferences, demonstrating leadership and a commitment to advancing cell biology research.

Research Focus:

Kai Zhao’s research centers on the molecular and cellular mechanisms driving disease, with an emphasis on mitophagy, exosomal biomarkers, and multi-omics analyses. They investigate how cellular quality control systems, such as the PINK1-mediated mitophagy pathway, contribute to neurodegenerative diseases and cancer progression, specifically osteosarcoma. By combining genomic, proteomic, and transcriptomic data, Kai aims to identify novel gene biomarkers within exosomes that can serve as diagnostic or therapeutic targets. One highlighted therapeutic candidate from their work is mifepristone, revealed through integrative multi-omics to be effective against osteosarcoma. Their research integrates cellular biology with clinical insights, particularly in bone metabolism and spinal diseases, aiming for translational impact. Overall, Kai’s focus is on uncovering how disruptions in cellular degradation and intercellular communication contribute to disease, leveraging multi-disciplinary approaches to develop targeted therapies.

Publication Top Notes:

    • Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi‐Omics Analysis

    • IRGM promotes the PINK1-mediated mitophagy through the degradation of Mitofilin in SH-SY5Y cells

Conclusion:

Kai Zhao is a promising and capable researcher whose work directly contributes to cutting-edge cell biology, particularly in disease mechanisms. Their multi-omics and cellular degradation studies mark them as an excellent candidate for the Cell Biology Research Award.

Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Published on by Cell Biologist

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Andrew Moran | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Andrew Moran | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Andrew Moran, University of Liverpool, United Kingdom

Dr. Andrew William Moran is a Research Associate at the University of Liverpool, UK, specializing in gastrointestinal physiology and nutrient sensing. With over two decades of research experience, his work has contributed significantly to understanding sugar sensing mechanisms and their implications for animal and human health. He holds dual honours in Biochemistry and Biological & Medicinal Chemistry from Keele University and a PhD in Biochemistry and Molecular Biology from the University of Liverpool. Dr. Moran has played key roles in industry-funded projects, notably with ADM International and Pancosma SA, contributing to patented innovations in sweetener technology. His cutting-edge research on intestinal transporters, gut hormones, and enteric nervous system function has led to over 20 peer-reviewed publications. His interdisciplinary collaborations span veterinary, nutritional, and molecular biology fields, making him a valuable asset in translational gastrointestinal science. His REF-submitted research underscores the real-world impact of his scientific contributions.

Publication Profile:  

Orcid

✅ Strengths for the Award:

  1. Robust Academic Foundation:

    • Dual honours in Biochemistry and Biological & Medicinal Chemistry (Keele University)

    • PhD in Biochemistry and Molecular Biology (University of Liverpool)

  2. Research Excellence & Impact:

    • Specializes in intestinal glucose transport, nutrient sensing, and gut-brain axis—key areas in both basic and applied science.

    • Authored 24 publications in Web of Science and 20 on PubMed, with an H-index of 15, indicating consistent impact.

  3. Translational & Applied Innovation:

    • Co-inventor on two international patents (WO2014033218A1 & WO2024121704A1) tied to sweetener additives—bridging lab discoveries with industrial application.

    • Projects funded by ADM International and Pancosma SA, highlighting industry trust.

  4. Collaborative Leadership:

    • Current research partnership with Dr. Ellen Roelfsema (Utrecht University) on metabolic syndrome in ponies—an example of cross-disciplinary collaboration.

    • Contribution to REF2021 and REF2024, showing national-level research evaluation engagement.

  5. Model Innovation:

    • Use of intestinal enteroids (mini-guts) in research, reflecting cutting-edge methodologies in gut physiology.

🧭 Areas for Improvement:

  • Editorial Leadership: There is no mention of editorial board roles or peer-review positions. Gaining visibility in editorial circles could amplify academic leadership.

  • Public Science Communication: While the research is strong, broader science communication (e.g., public outreach, open-access workshops, webinars) would further elevate his profile.

  • International Presence: While collaborations exist, a more visible presence through invited talks at global conferences or consortia could enhance reputation internationally.

🎓 Education:

Dr. Moran began his academic career with a BSc (Dual Honours) in Biochemistry and Biological & Medicinal Chemistry at Keele University from 1999 to 2002. He then pursued a PhD in Biochemistry and Molecular Biology at the University of Liverpool, completed in 2006. His doctoral work focused on molecular mechanisms governing intestinal function, laying the foundation for his future studies in gut nutrient sensing and transporter regulation. He has continually expanded his knowledge through postdoctoral training and research in gastrointestinal physiology. This includes both in vivo and in vitro experimental methodologies, ensuring a comprehensive approach to investigating intestinal health. His educational background supports a wide range of expertise—from fundamental biochemistry to applied animal nutrition and enteric neuroscience. His solid academic training is a core strength underpinning his contribution to translational and industry-focused research.

🧪 Experience:

Dr. Moran’s research experience spans over 20 years, with expertise in molecular physiology of the gastrointestinal system. Post-PhD, his early work investigated the regulation of intestinal SGLT1 transporters, combining cell-based and whole-organism experiments. From 2019 to 2022, he led a project exploring the adaptive responses of the gut to diet and development. His more recent work (2022–2024) focuses on sweetener additive development in swine, incorporating pig-specific intestinal enteroids. He is currently funded by ADM International and has previously collaborated with Pancosma SA, contributing to two international patents. Dr. Moran is also engaged in veterinary research, partnering with Utrecht University to study equine metabolic syndrome. He has served as both an academic researcher and a consultant on gut sensing and nutrient absorption. This blend of industry and academic experience strengthens his application for recognition as a leading researcher in the field of digestive sciences.

🔬 Research Focus:

Dr. Moran’s primary research interests lie in intestinal sugar and amino acid sensing, glucose transporter regulation, and the gut-brain axis. He uses both traditional and novel model systems, including intestinal enteroids (mini-guts), to explore physiological responses to dietary changes. His research particularly targets SGLT1 and GLUT2 transporters, sweet taste receptors (T1R2-T1R3), and enteroendocrine pathways, aiming to enhance feed efficiency and gut health in livestock. His focus on sweetener bioactivity has direct applications in agriculture and veterinary medicine. Additionally, Dr. Moran investigates how gut nutrient sensing influences systemic responses, including metabolic disorders like equine metabolic syndrome. By integrating biochemistry, molecular biology, and animal physiology, his research contributes to the development of functional feeds and dietary interventions. His work is highly translational, bridging laboratory research with field application, and has resulted in two patents, several international collaborations, and over 20 peer-reviewed journal articles, with research submitted for REF2021 and REF2024.

📚 Publications Top Notes:

  1. 📄 Luminal Sweet Sensing and Enteric Nervous System Participate in Regulation of Intestinal Glucose Transporter, GLUT2

  2. 📄 Nutrient sensing of gut luminal environment (Symposium: Proceedings of the Nutrition Society)

  3. 📄 Non-nutritive sweetener activation of the pig sweet taste receptor T1R2-T1R3 in vitro mirrors gut expression

  4. 📄 Toll-like receptor 9 in intestinal enteroendocrine cells induces cholecystokinin secretion

  5. 📄 High-Intensity Sweetener Enhances Intestinal SGLT1 and Improves Enteric Disorders in Rabbits

  6. 📄 Effect of Milk Replacer Composition on Intestinal Microbiota of Pre-ruminant Dairy Calves

  7. 📄 Host selectively shapes intestinal microbiota of carnivorous and omnivorous fish

  8. 📄 GLP-2 and Enteric Nervous System Regulate Intestinal Na+/Glucose Co-transport

  9. 📄 Deregulation of transcription factors in morbidly obese affects enteroendocrine cells

  10. 📄 Composition and diversity of pig gastrointestinal mucosa-associated microbiota under dietary influence

📝 Conclusion:

Dr. Andrew William Moran presents a strong and diverse research portfolio with a notable balance between fundamental science and industrial relevance. His innovation in nutrient sensing and gut physiology, coupled with active collaborations and patentable outputs, makes him an ideal candidate for the Best Researcher Award. With minor expansion in academic leadership and public engagement, Dr. Moran is poised to become a prominent figure in translational biosciences globally.

ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Published on by Cell Biologist

Prof. Dr. ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Prof. Dr. ASLI CEYLAN , Ankara Yildirim Beyazit University , Turkey

Dr. Aslı F. Ceylan is an accomplished pharmacologist and academic with a strong foundation in medical pharmacology and translational research. Born in Ankara, Turkey, in 1977, she has dedicated over two decades to advancing our understanding of cellular signaling pathways in disease states. After earning her degrees from Ankara University, she completed a prestigious postdoctoral fellowship at the University of Wyoming, where she began her international research journey. Currently serving at Ankara Yıldırım Beyazıt University School of Medicine, she contributes to both research and education. Fluent in Turkish, English, and Spanish, Dr. Ceylan bridges global scientific collaborations. Her work spans oxidative stress, inflammation, and cellular mechanisms in cardiovascular, metabolic, and neurodegenerative diseases. She is a prolific author and recipient of several international fellowships and project grants. Dr. Ceylan stands out as a dedicated scientist whose work contributes meaningfully to the field of signal transduction and molecular pharmacology.

Publication profile:

Orcid

✅ Strengths for the Award:

  1. Extensive Research in Signal Transduction Pathways
    Dr. Ceylan’s body of work demonstrates a consistent and high-impact focus on key signal transduction pathways—including NLRP3 inflammasome activation, mitophagy, ferroptosis, oxidative stress, and autophagy—across cardiovascular, metabolic, and neurological disease models.

  2. International Research Recognition
    She has held prestigious fellowships from NIH, the American Heart Association, and INBRE, contributing to globally relevant research while collaborating with international teams, especially in the U.S. and Europe.

  3. Strong Translational Relevance
    Her research links molecular mechanisms to potential therapies, such as her exploration of aldose reductase inhibitors, natural antioxidants, and neuroprotective compounds (e.g., rosemary extracts), bridging the gap between basic science and clinical relevance.

  4. Consistent Publication Record
    Dr. Ceylan has co-authored over a dozen peer-reviewed publications in the past three years alone, with topics directly tied to signal transduction, and published in reputable journals (e.g., Biochimica et Biophysica Acta, JACC: Basic to Translational Science).

  5. Leadership and Mentorship
    As a Principal Investigator for NIH-funded thematic research projects and an academic at a medical university, she demonstrates strong leadership, mentoring capabilities, and a sustained contribution to the scientific community.

🛠️ Areas for Improvement:

  1. Greater Focus on Human Clinical Studies
    While her animal model work is comprehensive, integrating more human cell or clinical data would increase the translational applicability of her research.

  2. Expanded Thematic Clarity in Signal Transduction
    Some of her recent works, while impactful, focus broadly on pharmacological effects of natural compounds. More thematic emphasis on specific intracellular signaling cascades (e.g., MAPK, PI3K/Akt, or JAK/STAT) could strengthen her profile specifically for a signal transduction-focused award.

  3. Visibility in Global Scientific Forums
    Increased participation as a speaker, panelist, or chair in international conferences focused on signal transduction would enhance her global academic footprint.

📘 Education:

Dr. Aslı F. Ceylan completed her entire academic training in Pharmacology at the prestigious Ankara University Faculty of Pharmacy. She earned her Bachelor of Science (B.Sc.) in Pharmacy in 1998, followed by a Master of Science (M.Sc.) in Pharmacology in 2001. Her strong interest in cellular mechanisms and drug interactions led her to pursue a Ph.D. in Pharmacology, which she successfully completed in 2007. Her doctoral research was further enhanced by a research fellowship at the National Institutes of Health (NIH) during 2004-2005, providing her hands-on experience in internationally recognized labs. This rigorous academic journey solidified her expertise in pharmacological mechanisms and preclinical modeling. Her academic training was consistently supported by competitive scholarships from the Turkish Scientific and Research Council (TÜBİTAK). Dr. Ceylan’s academic path reflects a deep commitment to understanding complex cellular systems and contributes significantly to her current role as a leader in molecular pharmacology and signal transduction.

💼 Experience:

Dr. Aslı F. Ceylan is currently a faculty member at Ankara Yıldırım Beyazıt University School of Medicine, where she serves in the Department of Medical Pharmacology. She has extensive academic and research experience spanning over 20 years. Her postdoctoral research at the University of Wyoming School of Pharmacy (2008–2009) focused on cardiovascular research, where she worked on signal transduction pathways involved in heart failure and metabolic disease. She also held a Principal Investigator (PI) role in NIH-funded INBRE research projects in the U.S. from 2011 to 2020. Dr. Ceylan has consistently contributed to multi-disciplinary research projects and collaborative studies, mentoring young researchers and postgraduate students. She has a solid background in oxidative stress, inflammation, and cellular apoptosis. Her translational approach, blending basic science with therapeutic innovation, aligns perfectly with the goals of signal transduction research. Her international exposure and consistent academic productivity make her a valuable asset to any scientific initiative.

🏆 Awards and Honors:

Dr. Aslı F. Ceylan has earned numerous national and international fellowships and honors throughout her career. She was awarded the Postdoctoral Fellowship by the American Heart Association and the University of Wyoming in 2008, which significantly propelled her research on cardiovascular signaling. She also received a Ph.D. research fellowship from the NIH (2004–2005), supporting her studies in cell signaling and oxidative stress. Domestically, she was funded by TÜBİTAK (Turkish Scientific and Research Council) for both her master’s and Ph.D. degrees. Most notably, she served as Principal Investigator for NIH INBRE Thematic Research Projects from 2011 to 2020, underlining her leadership and innovation in biomedical research. These accolades reflect her ongoing commitment to excellence in pharmacological science and her impact on the field of signal transduction, particularly in cardiovascular and neurodegenerative diseases. Her strong track record of competitive funding and recognition underscores her eligibility for the Signal Transduction Award.

🔬 Research Focus:

Dr. Ceylan’s research is centered on signal transduction pathways involved in oxidative stress, inflammation, mitophagy, and ferroptosis. Her work delves into the molecular mechanisms underlying cardiovascular diseases, diabetic complications, neurodegenerative disorders, and cancer, with a particular focus on mitochondrial function and cellular defense systems. She employs both in vivo and in vitro models to study how specific pharmacological agents modulate pathways like NLRP3 inflammasome activation, aldose reductase inhibition, and autophagy. Additionally, her recent research explores the therapeutic potential of natural compounds such as carnosol, carnosic acid, and rosemary extract in modulating redox balance and apoptotic pathways. Her interdisciplinary approach links natural product pharmacology with molecular signaling, making her contributions relevant across multiple domains. The translational value of her research, aiming to bridge the gap between bench and bedside, aligns directly with the core objectives of signal transduction studies and reinforces her eligibility for this distinguished award.

📚 Publications Top Notes:

  1. 🧬 Cardiomyocyte-specific deletion of endothelin receptor A obliterates cardiac aging via mitophagy and ferroptosis (2024)

  2. 🧫 Tackling chronic wound healing using nanomaterials: Advancements and future perspectives (2023)

  3. 🧪 Dual-acting aldose reductase inhibitor impedes oxidative stress in diabetic rat tissues (2023)

  4. 👁️ Cemtirestat induces ocular defense against glycotoxic stress in diabetic rats (2023)

  5. 🍷 NLRP3 inhibition protects against ethanol-induced cardiotoxicity in FBXL2-dependent manner (2023)

  6. 💉 Oxytocin and enalapril reduce epidural fibrosis post-laminectomy in rats (2023)

  7. 🧠 Calcium dobesilate therapy in cerebral hypoxia/reperfusion injury in rats (2023)

  8. 🧬 Beclin1 deficiency attenuates alcohol-induced cardiac dysfunction via ferroptosis inhibition (2022)

  9. 💓 Parkin insufficiency exacerbates cardiac remodeling through mitochondrial Ca2+ overload (2022)

  10. ❤️‍🩹 Beclin 1 haplosufficiency compromises stem-cell cardioprotection post-MI (2022)

🧾 Conclusion:

Dr. Aslı F. Ceylan is a highly qualified, internationally active, and academically productive researcher whose expertise lies in elucidating molecular mechanisms of disease through signal transduction pathways. Her deep involvement in studies on oxidative stress, mitochondrial dynamics, inflammation, and natural product pharmacology positions her as a valuable contributor to the advancement of molecular medicine.

Given her research output, grant leadership, and commitment to translational science, she is highly suitable for the Signal Transduction Award. Her work not only contributes to the understanding of intracellular signaling but also bridges basic research with therapeutic potential, making her a standout candidate for this recognition.

Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Prof. Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Raphaël Rodriguez , CNRS, Institut Curie, France

Raphaël Rodriguez, born October 27, 1978, in Avignon, France, is a pioneering chemical biologist and Research Director at CNRS, Principal Investigator at Institut Curie, and holder of the Skłodowska-Curie Chair of Chemical Biology. A French citizen with two children, Lucía del Mar and Aramis, Rodriguez is renowned for bridging chemistry and biology to unlock the molecular secrets of cancer and inflammation. Trained in the UK under legendary scientists Sir J. E. Baldwin, Sir S. Balasubramanian, and Sir S. P. Jackson, he returned to France to launch groundbreaking research on ferroptosis and metal regulation in cell adaptation. His entrepreneurial and academic excellence earned him numerous accolades, including the National Order of Merit. With more than 130 publications and several successful biotech ventures, Rodriguez continues to shape the future of medical science with bioactive molecules like Ironomycin and Pyridostatin. He is an editorial board member, reviewer, teacher, and a public voice on science.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Pioneering Scientific Impact:
    Dr. Rodriguez has contributed over 130 high-impact publications in top-tier journals like Nature, Science, JACS, Nature Chemistry, and Cell Metabolism. His work has helped define ferroptosis, a form of programmed cell death, and metal regulation in cancer—a game-changing area in molecular medicine.

  2. Innovation & Translation:
    He discovered and commercialized small molecules such as Pyridostatin, Ironomycin, and Supformin, directly impacting both science and therapeutics. His work bridges fundamental science and drug discovery.

  3. Leadership & Mentorship:
    From mentoring under renowned scientists to leading his own lab at Institut Curie, he has shaped France’s next generation of researchers in chemical biology.

  4. Recognition & Awards:
    His extensive list of prestigious awards, including the CNRS Silver Medal, Liliane Bettencourt Prize, and Knight of the National Order of Merit, reflect peer recognition on national and international levels.

  5. Entrepreneurship:
    As a co-founder of biotech companies (e.g., Adrestia Therapeutics, later acquired), he has demonstrated a rare capacity to translate discoveries into clinical and commercial value.

  6. Scientific Influence:
    Editorial board memberships and frequent invitations to over 160 major conferences show his reputation as a global thought leader in his field.

🔧 Areas for Improvement:

  1. Public Engagement Scaling:
    Although Dr. Rodriguez is active in media (radio, TV, print), expanding international science outreach (e.g., global science festivals, public lectures, social media presence) could help further democratize his scientific message.

  2. Clinical Translation:
    While several molecules from his lab are commercialized, more direct clinical trials or FDA approvals tied to his molecules would elevate his impact from bench to bedside.

  3. Collaborative Diversity:
    Encouraging more global South collaborations or mentorships could help broaden his lab’s international footprint and contribute to equitable science capacity building.

🎓 Education:

Raphaël Rodriguez’s academic journey is marked by elite training and impactful credentials across Europe. He earned his PhD in Chemistry (2002–2005) through a joint program between Marseille and Oxford. He then pursued postdoctoral research as a Senior Research Associate at Cambridge’s Department of Chemistry and Gurdon Institute (2005–2012), where he developed skills at the interface of chemistry and biology. In 2012, he obtained the prestigious Habilitation à Diriger des Recherches from the University of Paris-Saclay, enabling him to supervise PhD candidates and lead independent research. His rise through the academic ranks was rapid: he became a CNRS Group Leader in 2012, then Principal Investigator at Institut Curie in 2015. In 2017, he was promoted to Research Director (DR1) at CNRS. In 2020, he was awarded the Skłodowska-Curie Chair of Chemical Biology at Institut Curie. His interdisciplinary training under world-renowned mentors has uniquely positioned him at the forefront of chemical biology research.

💼 Experience:

Raphaël Rodriguez’s professional experience is a blend of high-level research, leadership, and innovation. He began his postdoctoral career at the University of Cambridge (2005–2012), working in the Department of Chemistry and the Gurdon Institute. In 2012, he became a CNRS Group Leader at ICSN, Gif-sur-Yvette, launching his independent research career. In 2015, he transitioned to Institut Curie as a Principal Investigator, where he deepened his focus on cancer and inflammation. His promotion to Research Director (DR1) at CNRS in 2017 reflects his impact and leadership. Awarded the Skłodowska-Curie Chair of Chemical Biology in 2020, Rodriguez oversees a productive lab that investigates ferroptosis, DNA structure, and metal ion regulation in disease. He is also an entrepreneur, co-founding Adrestia Therapeutics and OrbiThera. He teaches at PSL University, organizes international conferences, and contributes to editorial boards and scientific advisory boards worldwide, maintaining a strong presence in both academia and biotech.

🏆 Awards and Honors:

Raphaël Rodriguez has received an impressive array of honors, showcasing his impact on science and innovation. In 2024 alone, he won the CNRS Silver Medal and the Ligue Contre le Cancer Duquesne Prize. His earlier recognition includes the prestigious Liliane Bettencourt Prize for Life Sciences (2023), the Knight of the National Order of Merit (2022, presented by Nobel Laureate Jean-Marie Lehn), and the Klaus Grohe Prize (2022). He has also been awarded the Antoine Lacassagne Prize (Collège de France, 2019), the Sunrise Cancer Stem Cell Award (2019), the Charles Defforey–Institut de France Prize (2019), and the Tetrahedron Young Investigator Award (2019). Rodriguez is a Fellow of the Royal Society of Chemistry (2018) and won the Pierre Fabre Award for Therapeutic Innovation (2015). These accolades affirm his contributions across cancer research, chemical biology, and molecular therapeutics, as well as his success in translating science into societal benefit through entrepreneurship.

🔍 Research Focus:

Raphaël Rodriguez’s research lies at the cutting edge of chemical biology, with a focus on understanding how cells adapt to stress, particularly in the contexts of cancer and inflammation. His laboratory explores the role of metal ions—especially iron—as regulators of cellular plasticity and fate. Notably, his team discovered mechanisms underlying ferroptosis, a form of regulated cell death linked to iron metabolism, and how this can be exploited for anti-cancer therapies. He also investigates non-canonical DNA structures like G-quadruplexes, using small molecules to study and manipulate gene regulation. His lab has developed and commercialized several potent bioactive compounds, including Pyridostatin, Remodelin, Ironomycin, and Supformin, which are used both as research tools and potential therapeutics. Rodriguez combines molecular design, cell biology, and translational strategies, making his work a blueprint for chemical biology-driven precision medicine. He continues to raise significant research funding and actively collaborates across academia and biotech.

📚 Publications Top Notes:

  1. 🧬 Small-molecule–induced DNA damage identifies alternative DNA structures in human genes – Nature Chemical Biology

  2. ⚙️ Salinomycin kills cancer stem cells by sequestering iron in lysosomes – Nature Chemistry

  3. 🛡️ A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres – JACS

  4. 🧫 Chemical inhibition of NAT10 corrects defects of laminopathic cells – Science

  5. 🧠 The transcription factor FOXM1 is a cellular target of the natural product thiostrepton – Nature Chemistry

  6. 🧪 Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands – JACS

  7. 🔥 PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers – Cell Metabolism

  8. 🔬 A single-molecule platform for investigation of G-quadruplex interactions with small-molecule ligands – Nature Chemistry

  9. 🧲 Small-molecule-mediated G-quadruplex isolation from human cells – Nature Chemistry

  10. 🧬 CD44 regulates epigenetic plasticity by mediating iron endocytosis – Nature Chemistry

  11. 🧷 Selective RNA vs DNA G-Quadruplex Targeting by In Situ Click Chemistry – Angewandte Chemie

  12. 🧬 G-Quadruplex-Binding Benzo[a]phenoxazines Down-Regulate c-KIT Expression in Gastric Carcinoma Cells – Journal of Medicinal Chemistry

🧾 Conclusion:

Dr. Raphaël Rodriguez exhibits exceptional merit and impact across the entire research ecosystem—fundamental science, innovation, mentorship, and commercialization. His trailblazing work in chemical biology, coupled with a record of scientific leadership and entrepreneurship, makes him highly deserving of the Best Researcher Award. His career reflects a rare blend of depth, vision, and cross-disciplinary innovation. Minor enhancements in global public engagement and clinical integration could further elevate his already stellar profile.